Trial Profile
The Effect of Recombinant Human Thrombopoietin(rhTPO) on Sepsis Patients With Acute Severe Thrombocytopeniaa Prospective, Multi-center, Open-label, Randomized, Controlled Trial
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 01 Nov 2022
Price :
$35
*
At a glance
- Drugs Thrombopoietin (Primary)
- Indications Thrombocytopenia
- Focus Therapeutic Use
- Acronyms RESCUE
- 25 Oct 2022 Planned End Date changed from 30 Dec 2022 to 30 Apr 2023.
- 25 Oct 2022 Planned primary completion date changed from 30 Nov 2022 to 31 Mar 2023.
- 22 Feb 2021 Planned End Date changed from 1 Oct 2021 to 30 Dec 2022.